Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
1998-12-15
2003-12-30
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S455000, C435S456000
Reexamination Certificate
active
06669935
ABSTRACT:
This invention relates to gene therapy for treatment of a disease or disorder by delivering therapeutic agents to the brain. More particularly, this invention relates to gene therapy through delivery of therapeutic agents to the brain by transducing endothelial cells of blood vessels located in the brain in vivo with a vector, wherein the vector is administered intravascularly. The invention further relates to treatment of tumors by transducing gene therapy wherein endothelial cells of blood vessels of the tumor are transduced with a polynucleotide expressing a therapeutic agent.
This invention further relates to the treatment of brain tumors by gene therapy wherein endothelial cells of blood vessels located in a brain tumor are transduced with a vector which includes a polynucleotide encoding an agent which when expressed provides for inhibition, prevention or destruction of the tumor. The vector is administered intravascularly. The agent may be a negative selective marker. Upon administration of an interaction agent to the host, the growth of the brain tumor is inhibited, prevented, or destroyed, thereby leading to regression of the tumor.
BACKGROUND OF THE INVENTION
Gene therapy has been used to deliver a therapeutic agent to the brain by in vivo transduction of cells which involves direct injection of a suitable vector into cells located in the brain, e.g., injection of the vector into tumor cells located in the brain.
There is a need for improved procedures for using gene therapy for delivering a therapeutic agent to the brain and in particular for the treatment of brain tumors by gene therapy which does not require direct introduction of a vector into the brain.
REFERENCES:
patent: 476953 (1992-03-01), None
patent: WO93/04167 (1993-03-01), None
patent: WO93/10234 (1993-05-01), None
Dang, V.C. et al. Gene therapy and translational cancer research. Clin. Cancer Res. 5:471-474, 1999.*
Wivel, N.A. & Wilson, J.M. Methods of gene delivery. Hematol. Oncol. Clin. North Am. 12:483-501, 1998.*
Eck, S.L. & Wilson, J.M. Gene-based therapy. Goodman & Gilman's The pharmacological basis of therapeutics, Ninth edition, pp. 77-101, 1996.*
Weyerbrock, A. & Oldfield, E.H. Gene transfer technologies for malignant gliomas. Curr. Opin. Oncol. 11:168-173, 1999.*
Rainov, G.N. et al. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum. Gen. Ther. 10:311-318, 1999.*
McCluskie et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5:287-300, 1999.*
Ram, Z. et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg 81:256-260, 1994.*
Lemarchand, P. et al. Adenovirus-mediated transfer of a recombinant human alpha 1-anti-trypsin cDNA to human endothelial cells. Proc. Natl. Acad. Sci. 89:6482-6486, 1992.*
Steg, P.G. et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using perc utaneous delivery of an adenoviral vector. Circulation 90:1648-1656, 1994.*
Palmer et al.; Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes, 1991, Proc. Natl. Acad. Sci. vol. 88: 1330-1334.*
Miller et al.; Targeted vectors for gene therapy, 1995, FASEB J. 9: 190-199.*
Verma et al.; Gene therapy-promises, problems and prospects, 1997, Nature vol. 389:239-242.*
Deonarain; LIgand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8(1): 53-69.*
Marshall; Gene Therapy's Growing Pains, 1995, Science vol. 269; 1050-1055.*
Short, et al.,Journal of Neuroscience Research, vol. 27, pp. 427-439 (1990).
Ezzedine, et al.,New Biologist, vol. 3, pp. 608-614 (1991).
Culver, et al.,Science, vol. 256, pp. 1550-1552 (Jun. 1992).
Ram, et al.,Cancer Research, vol. 53, pp. 83-88 (Jan. 1, 1993).
Neuwelt, et al.,Neurosurgery, vol. 34, No. 4, pp. 777-784 (Apr. 1994).
Lowenstein,Biotechnology, vol. 12, pp. 1075-1079 (Nov. 1994).
McGarrity Gerard J.
Oldfield Edward H.
Ram Zvi
Guzo David
Klarquist & Sparkman, LLP
Nguyen Quang
The United States of America as represented by the Department of
LandOfFree
Delivery of therapeutic agents by gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of therapeutic agents by gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of therapeutic agents by gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3158480